文献速递类风湿关节炎其他结缔组织病血管炎

新型糖皮质激素特异性患者报告结局问卷(Steroid PRO)的验证

Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO).
PubMed 文献 · Ann Rheum Dis · 2024-02-15

该研究基于英国、美国、澳大利亚和新西兰946例因风湿病使用糖皮质激素的成人横断面调查,评估Steroid PRO量表的心理测量学特性。经Rasch模型剔除25个条目后,探索性因子分析提示4个子量表共15个条目,总分组内相关系数为0.809。结论认为Steroid PRO是测量糖皮质激素治疗对风湿病患者影响的有效可靠量表。

要点

  • Steroid PRO最终包含15个条目,分为社会影响、外观影响、心理影响和治疗担忧4个子量表。
  • Rasch模型支持四子量表结构及总分,证实结构效度和信度。
  • 总分组内相关系数为0.809,显示重测信度优秀。

核心结论

  • Steroid PRO是包含15个条目的有效且可靠的量表,用于测量糖皮质激素治疗对风湿病患者的影响。

研究设计与样本

  • 横断面调查纳入英国、美国、澳大利亚和新西兰因风湿病使用糖皮质激素的成人,共946例应答。
  • 初次调查收集人口学、临床信息、40个Steroid PRO候选条目和EQ-5D-5L,3-5天后随访收集候选条目和病情变化问题。
  • 分析采用Rasch测量模型、探索性因子分析及区分效度、收敛效度和重测信度的假设检验。

主要发现

  • 总应答946例:英国743例(79%),美国139例(15%),澳大利亚/新西兰64例(7%);平均年龄57.6岁(SD=13.6);女性833例(88%)。
  • 炎症性关节炎197例(21%),结缔组织病和/或血管炎402例(42%),巨细胞动脉炎和/或风湿性多肌痛347例(37%)。
  • 25个条目因不符合Rasch模型被剔除。
  • 探索性因子分析提示4个子量表:社会影响(4条目)、外观影响(3条目)、心理影响(5条目)、治疗担忧(3条目)。
  • Rasch模型支持四子量表结构及总分,证实结构效度和信度;假设检验证实区分效度和收敛效度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Glucocorticoids used in the treatment of inflammatory rheumatic conditions can impact on health-related quality of life. An underpinning qualitative study developed a long-list of candidate items for a treatment-specific patient-reported outcome (PRO) measure. The objective of this paper is to determine scale structure and psychometric properties of the Steroid PRO. METHODS: A cross-sectional survey of adults from the UK, USA, Australia and New Zealand, taking glucocorticoids for a rheumatic disease. Initial survey collected demographics, clinical information, 40 Steroid PRO candidate items and EuroQol-5 Dimensions- 5 levels (EQ-5D-5L). Follow-up, 3-5 days later, collected Steroid PRO candidate items and a condition-change ('transition') question. Analysis included Rasch measurement model, exploratory factor analysis (EFA), and hypothesis testing for discriminative validity, convergence validity and test-retest reliability. RESULTS: Total responses 946: UK n=743 (79%); USA n=139 (15%); Australia/New Zealand n=64 (7%); mean age 57.6 (SD=13.6); 833 (88%) women. Participants with inflammatory arthritis n=197 (21%), connective tissue disease and/or vasculitis n=402 (42%), giant cell arteritis and/or polymyalgia rheumatica n=347 (37%). Twenty-five items were removed due to lack of fit to Rasch model. Of the remaining items, EFA suggested four subscales: Social impact (4 items); Impact on appearance (3 items); Psychological impact (5 items); Treatment concerns (3 items). Rasch modelling supported a four-subscale structure and total score, confirming construct validity and reliability. Hypothesis testing confirmed discriminant and convergence validity. Intraclass correlation coefficient (total score) was 0.809 demonstrating excellent (test-retest) reliability. CONCLUSIONS: The Steroid PRO is a 15-item, valid and reliable scale for measuring the impact of glucocorticoid therapy in people with rheumatic diseases.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Bridgewater S, Ndosi M, Dawson J, et al. Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO). Ann Rheum Dis. 2024. PMID: 37949468. doi:10.1136/ard-2023-224946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。